Doggrell S A, Hughes E W
J Auton Pharmacol. 1985 Dec;5(4):279-88. doi: 10.1111/j.1474-8673.1985.tb00551.x.
The effects of labetalol and its R1R isomer, SCH 19927, on the accumulation of radioactivity from [3H]-noradrenaline, and on the subsequent spontaneous and nerve-evoked outflow of radioactivity have been investigated in the rat isolated right ventricle. In addition, the effect of these agents on the contractions of the electrically-driven rat right ventricle to isoprenaline and of the rat isolated aorta to phenylephrine and 5-hydroxytryptamine are reported. Labetalol and SCH 19927 (both at 10(-6)M) inhibited the accumulation of radioactivity from [3H]-noradrenaline by 26 and 37%, respectively. The spontaneous outflow of radioactivity, following loading of the ventricle with [3H]-noradrenaline, was increased by labetalol and SCH 19927 (both at 10(-6)M) by a cocaine and idazoxan-insensitive mechanism. The nerve-evoked outflow of radioactivity was increased by labetalol and SCH 19927 (both at 10(-6)M). The ability of labetalol and SCH 19927, to increase nerve-evoked outflow was maintained in the presence of cocaine (10(-5)M) or idazoxan (10(-7)M) but reversed in the presence of cocaine and idazoxan. It is suggested that labetalol and its R1R isomer act both to inhibit neuronal uptake of noradrenaline and as antagonists at prejunctional alpha 2-adrenoreceptors. Labetalol and SCH 19927 reduced the contractile responses associated with the nerve-evoked outflow of radioactivity probably mainly by acting as antagonists at postjunctional beta 1-adrenoreceptors. The contractile responses of the electrically-driven rat right ventricle to isoprenaline were inhibited by labetalol and SCH 19927. SCH 12297 (pA2 = 8.9) was 4 times more potent than labetalol (pA2 = 8.3) as a beta 1-adrenoreceptor antagonist. The ability of labetalol and SCH 19927 at greater than or equal to 10(-7)M to depress maximal responses to isoprenaline may represent membrane stabilizing activity. The contractile responses of rat aorta to phenylephrine were inhibited by labetalol and SCH 19927. Labetalol (pA2 = 7.5) was 4X more potent than SCH 19927 (pA2 = 6.9) as an alpha 1-adrenoreceptor antagonist. SCH 19927 and labetalol had no effect on contractile responses to 5-hydroxytryptamine.
在大鼠离体右心室中,研究了拉贝洛尔及其R1R异构体SCH 19927对[3H]-去甲肾上腺素放射性积聚的影响,以及对随后放射性物质的自发和神经诱发流出的影响。此外,还报道了这些药物对电驱动的大鼠右心室对异丙肾上腺素的收缩作用以及对大鼠离体主动脉对去氧肾上腺素和5-羟色胺的收缩作用的影响。拉贝洛尔和SCH 19927(均为10(-6)M)分别抑制了[3H]-去甲肾上腺素放射性积聚的26%和37%。在用[3H]-去甲肾上腺素加载心室后,拉贝洛尔和SCH 19927(均为10(-6)M)通过一种对可卡因和咪唑克生不敏感的机制增加了放射性物质的自发流出。拉贝洛尔和SCH 19927(均为10(-6)M)增加了神经诱发的放射性流出。拉贝洛尔和SCH 19927增加神经诱发流出的能力在存在可卡因(10(-5)M)或咪唑克生(10(-7)M)时得以维持,但在同时存在可卡因和咪唑克生时则被逆转。提示拉贝洛尔及其R1R异构体既作用于抑制去甲肾上腺素的神经元摄取,又作为突触前α2-肾上腺素能受体拮抗剂。拉贝洛尔和SCH 19'927可能主要通过作为突触后β1-肾上腺素能受体拮抗剂来降低与神经诱发的放射性流出相关的收缩反应。拉贝洛尔和SCH 19927抑制了电驱动的大鼠右心室对异丙肾上腺素的收缩反应。作为β1-肾上腺素能受体拮抗剂,SCH 12297(pA2 = 8.9)的效力比拉贝洛尔(pA2 = 8.3)强4倍。拉贝洛尔和SCH 19927在大于或等于10(-7)M时降低对异丙肾上腺素最大反应的能力可能代表膜稳定活性。拉贝洛尔和SCH 19927抑制了大鼠主动脉对去氧肾上腺素的收缩反应。作为α1-肾上腺素能受体拮抗剂,拉贝洛尔(pA2 = 7.5)的效力比SCH 19927(pA2 = 6.9)强4倍。SCH 19927和拉贝洛尔对5-羟色胺的收缩反应没有影响。